Transforming the linkage to care
MagIA diagnostics Point-of-care screening will transform the way patients are linked to care
multiplexed
4 to 8 parameters at once
Broad screening campaigns
fast
Results given in 12 minutes
Just in time for a consultation
small sample
Just 50 µl of capillary blood
Easy to use and non-invasive
portable
A system weight below 3 kg
Get it done wherever needed
Syndromic testing
MagIA diagnostics offers a new approach allowing the screening of HIV and its coinfections hepatitis B and C in a single test using capillary blood. With its ability to test 2 cartridges at the same time, our system to test up to 8 markers at the point of care. Our portable and syndromic approach provides benefits to healthcare professionals allowing more people to be tested in less time, resulting in a better linkage to care of the patients.
One system – endless testing
MagIA diagnostics will offer a large panel of syndromic testing panels – all based on the same analyzer
Analyzer
Disrupting today’s blood-testing standards, the MagIA diagnostic Analyzer brings laboratory quality testing to the Point-of-Care. Compared to lateral flow assay, our device-based approach allows for a simplified and enhanced traceability of patient data. This portable system is designed for effortless and straightforward operation, making it suitable for both medical and non-medical professionals
Non-contractual visuals / Product not CE marked
Non-contractual visuals / Product not CE marked
Latest news
The latest updates from MagIA diagnostics
Q&A sur Wiseed
Comme vous le savez MagIA diagnostics est actuellement en levée de fonds avec l'aide la plateforme de crowdfunding WiSEED.A cette occasion Paul et Cédric se sont prêtés au jeu des questions / réponses, pour les futurs investisseurs de la plateforme, à l'aide d'une...
Interview de Paul Kauffmann sur France Bleue Isère
La Nouvelle éco en Isère : MagIA diagnostics, spécialiste du dépistage rapide, lance sa phase industrielle (francebleu.fr)
Grand Défi Bioproduction
MagIA diagnostics a été retenue par le Grand Défi Bioproduction (Secrétariat général pour l'investissement) dans le cadre d’un appel à projet. Le projet porte sur l’adaptation de sa technologie pour en faire un outil de mesure de biomédicaments (anticorps...